Raymond Debbane is Director at LEXICON PHARMACEUTICALS, INC./DE (LXRX). They have made 14 open-market trades across 3 companies since 2010, most recently 2026-06-03.
CIK 0001053890
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
14 open-market purchases totalling $124.6M since 2010, never a sale. Across 14 scored buys the stock is up 25.3% at ninety days, and 21.1 points ahead of the S&P over the same stretch.
14 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| WTW | 33,426 | $10.5M |
| LXRX | 1,995,498 | $3.0M |
| WW | 134,387 | $1.7M |
| BUFF | 10,569 | $571K |
| Total | $15.9M |
Shares reported on the most recent Form 4, priced at the 2026-06-04 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 79% | 86% | 86% |
| Avg Move | +4.6% | +3.6% | +25.3% |
| Alpha | +5.8% | +5.8% | +21.1% |
| Scored | 14 | 14 | 14 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LXRX | BUY | 2026-02-25 | 2026-02-27 | $1.49 | $3K | +21.1% | +7.0% | +55.6% |
| LXRX | BUY | 2026-02-23 | 2026-02-25 | $1.47 | $147K | +13.5% | +11.5% | +39.2% |
| LXRX | BUY | 2026-02-19 | 2026-02-23 | $1.47 | $220K | +8.6% | +11.6% | +36.4% |
| LXRX | BUY | 2026-02-13 | 2026-02-18 | $1.31 | $353K | +9.9% | +9.9% | +49.3% |
| LXRX | BUY | 2023-10-10 | 2023-10-12 | $1.10 | $2.2M | +4.4% | -6.1% | +27.2% |
| WW | BUY | 2022-11-10 | 2022-11-15 | $4.27 | $641K | -11.7% | -16.0% | +2.1% |
| LXRX | BUY | 2022-08-05 | 2022-08-09 | $2.50 | $368K | +15.8% | +7.5% | -19.6% |
| LXRX | BUY | 2022-08-01 | 2022-08-01 | $2.50 | $2.5M | +8.2% | +7.8% | -15.7% |
| LXRX | BUY | 2019-09-13 | 2019-09-17 | $2.69 | $278K | +10.8% | +5.2% | +56.5% |
| LXRX | BUY | 2019-09-13 | 2019-09-17 | $2.40 | $333K | +10.8% | +5.2% | +56.5% |
| LXRX | BUY | 2019-09-13 | 2019-09-17 | $2.40 | $476K | +10.8% | +5.2% | +56.5% |
| WTW | BUY | 2016-03-01 | 2016-03-03 | $12.03 | $2.0M | +3.5% | +0.9% | +9.8% |
| LXRX | BUY | 2012-10-23 | 2012-10-25 | $2.25 | $6.8M | -21.0% | +0.6% | +0.6% |
| LXRX | BUY | 2010-03-19 | 2010-03-19 | $1.15 | $108.4M | -21.0% | +0.6% | +0.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.